In addition to inflammatory responses, the effects of GPR4 antagonists on other COVID-19 complications such as blood vessel permeability, lung edema, vascular thromboembolism, and pain can also be evaluated in these preclinical animal models. The gene discussed is GPR4; the disease is Thromboembolism.